Celerion’s combination of experienced people, scientific excellence and state-of-the-art facilities strongly positions us as an industry leader in the conduct of early clinical research and bioanalytical studies.
Experience and expertise
Leadership with extensive depth and breadth of experience in drug development
Clinical study design, execution and analysis that leverages the scientific experience of our staff
Over 25 years’ experience in conducting over 600 First-In-Human studies to provide confidence that the inherent risks of early clinical research are clearly understood and well managed
One of the largest Clinical Pharmacology Sciences teams in the industry, evaluating over 400 protocols per year and producing over 200 reports annually
Drug Development consultants that help clients establish product value through design and execution of an integrated program of studies focusing on demonstrating early evidence of drug safety and effect
Regulatory strategy and technical support for INDs and CTAs in North America and Europe
Scientific excellence that leverages innovative technologies
Market leader in early cardiac studies – first CRO with a Hybrid Phase I/ ECG Core lab utilizing Bluetooth Holter monitors and automated ECG review that benefit clients with faster access to data, lower costs and higher quality data
Deployment of electronic lab notebooks in our global bioanalytical facilities drives efficiency and fast turnaround of PK information for early clinical research decisions
Utilization of radioactive microtracers in early clinical research at our regulated clinic facilities enables understanding pharmacokinetic and metabolism questions early; full capabilities for performing comprehensive ADME programs
Addition of a USP Clean Room to Celerion’s Phase I core capabilities, enables sterile extemporaneous compounding in-house for microtracer studies. Clients benefit by accessing quality data earlier in drug development process
Strategically located state-of-the-art facilities
Global network includes sites in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Belfast, Northern Ireland UK and Zurich, Switzerland; as well as operations in Richmond, Virginia and Montreal, Canada
Large global clinic presence operating under a common recruiting database and SOPs to enable flexible and effective subject enrollment
Purpose-built facilities with co-located pharmacies, clinical laboratories, clinical conduct areas, bioanalysis laboratories, and clinical pharmacology sciences to expedite drug development
